Table 2.

Additional Characteristics of the Prostate Cancer Screening Decision-Making Process

Characteristic	Control Group (n = 75)	Brochure Group (n = 196)	Web Site Group (n = 226)
Patients reported reviewing educational material before visit, %	46	88	85
PSA test ordered
Patient report, %	85	83	86
Physician report, %	94*	85†	86‡
Relative frequency no time (0 minutes) was spent discussing prostate cancer
Patient report, %	2.7	1.0	3.1
Physician report, %	1.3	0.5	0.9
Minutes spent discussing prostate cancer
Patient report, mean (range)	5.2 (0–20)	5.3 (0–25)	5.1 (0–15)
Physician report, mean (range)	4.2 (0–30)	3.8 (0–15)	3.7 (0–20)
Number of prostate cancer topics discussed§
Patient report, mean (range)	4.3 (0–10)	4.9 (0–10)	5.0 (0–10)
Physician report, mean (range)	5.2 (0–10)	5.1 (0–10)	5.0 (0–10)
Percentage of knowledge questions patient answered correctly	54||	69	69
Patient DCS score, mean (range)	1.58 (1–3.2)	1.54 (1–2.8)	1.55 (1–2.7)

PSA = prostate-specific antigen; DCS = Decisional Conflict Scale.

* Control group: patient-reported vs physician-reported frequency of PSA testing (P = .06).

† Physician-reported frequency of PSA testing: brochure group vs control group (P = .04).

‡ Physician-reported frequency of PSA testing: Web site group vs control group (P = .06).

§ Potential range: 0 to 10.

|| Control vs brochure group (P <.001); control vs Web site group (P <.001).